Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | XBP1 | P17861 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1642435 | 0.94 | MAPT (0.57) | MAPTHTTXBP1TSHRKMT2A | |
| SCHEMBL1642943 | 0.90 | LMNA (0.56) | MAPTHTTXBP1TSHRKMT2A | |
| SCHEMBL3964774 | 0.85 | MAPT (0.82) | MAPTHTTXBP1KMT2AMEN1 | |
| SCHEMBL1642960 | 0.84 | TSHR (0.58) | MAPTHTTXBP1TSHRKMT2A | |
| SCHEMBL4012507 | 0.79 | MAPT (0.72) | MAPTHTTXBP1KMT2AMEN1 | |
| SCHEMBL1676994 | 0.79 | MAPT (0.61) | MAPTHTTXBP1TSHRKMT2A | |
| SCHEMBL3486038 | 0.77 | TSHR (0.59) | MAPTHTTXBP1TSHRALDH1A1 | |
| SCHEMBL1677098 | 0.77 | TP53 (0.54) | MAPTHTTXBP1TSHRKMT2A | |
| SCHEMBL2291103 | 0.77 | KMT2A (0.56) | MAPTHTTXBP1TSHRKMT2A | |
| SCHEMBL1642489 | 0.77 | LMNA (0.59) | MAPTHTTXBP1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399486-B2 | Benzenesulfonyl compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2013-03-19 | — | — | US | claimed |
| US-20110098281-A9 | Benzenesulfonyl Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2011-04-28 | — | — | US | claimed |
| US-20100063030-A1 | Benzenesulfonyl Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2010-03-11 | — | — | US | claimed |
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | US | disclosed |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-01-20 | — | — | US | disclosed |
| US-20210290561-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210030695-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-02-04 | — | — | US | disclosed |
| US-10729664-B2 | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190216747-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION | 2019-07-18 | — | — | US | disclosed |
| EP-3485881-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | President and Fellows of Harvard College (US) | 2019-05-22 | — | — | EP | disclosed |
| EP-2995303-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | President and Fellows of Harvard College (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20120172429-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI- INFLAMMATORY AGENTS | THE GENERAL HOSPITAL CORPORATION | 2012-07-05 | — | — | US | disclosed |
| US-20110098281-A9 | Benzenesulfonyl Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098281-A9 | Benzenesulfonyl Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098281-A9 | Benzenesulfonyl Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2011006073-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-01-13 | — | — | WO | disclosed |
| US-20100063030-A1 | Benzenesulfonyl Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063030-A1 | Benzenesulfonyl Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063030-A1 | Benzenesulfonyl Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2010-03-11 | — | — | US | disclosed |
| WO-2008124118-A1 | BENZENESULFONYL COMPOUNDS AND THE USE THEROF | PURDUE PHARMA L.P. (DE) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172429-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI- INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | MAPT 725/4885HTT 1326/4885XBP1 3436/4885 |
| US-10729664-B2 | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents | TRPV1, CACNA1B, ORAI1 | MAPT 725/4885HTT 1326/4885XBP1 3436/4885 |
| US-20110098281-A9 | Benzenesulfonyl Compounds and the Use Thereof | CACNA1A, CACNA1I, TRPV1 | MAPT 4473/4885HTT 2983/4885XBP1 2634/4885 |
| US-20210030695-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | MAPT 725/4885HTT 1326/4885XBP1 3436/4885 |
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | OPRL1, MRGPRX1, RAMP1 | MAPT 3141/4885HTT 2729/4885XBP1 915/4885 |
| US-20100063030-A1 | Benzenesulfonyl Compounds and the Use Thereof | CACNA1A, CACNA1I, TRPV1 | MAPT 4473/4885HTT 2983/4885XBP1 2634/4885 |
| US-20190216747-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | MAPT 725/4885HTT 1326/4885XBP1 3436/4885 |
| US-20210290561-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | MAPT 725/4885HTT 1326/4885XBP1 3436/4885 |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CACNA1B, TRPV1, ORAI1 | MAPT 716/4885HTT 1262/4885XBP1 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.